Skip to main content
MedPathMedPath Home
Clinical Trials/PACTR202204600690227
PACTR202204600690227
Not yet recruiting
Phase 2

COMPASSIONATE COVID-19 TREATMENT PROJECT INTENDED TO EVALUATE SAFETY AND EFFICACY OF THE NIMRCAF, COVIDOL AND BUPIJI OIL – THE HERBAL PREPARATIONS FOR THE TREATMENT OF COVID-19 PATIENTS

Kilimanjaro Clinical Research Institute0 sites416 target enrollmentMarch 22, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Kilimanjaro Clinical Research Institute
Enrollment
416
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 22, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Confirmed COVID\-19 patients aged eighteen years and above
  • •Hospitalized and with moderate or severe form of disease, during the study period at any of the study sites
  • •Consented participant

Exclusion Criteria

  • •Unconsented participant
  • •Patient with any clinically significant Grade 3 or 4 laboratory abnormality according to the Division of AIDS (DAIDS) grading scale
  • •Patient aged less than eighteen years
  • •Patient with peptic ulcers
  • •History of using any of the investigational herbal preparations
  • •Pregnant women
  • •COVID\-19 patients with mild signs and symptoms

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Ozone Therapy for Covid 19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
CTRI/2020/07/026671Bisleri charitable trust
Recruiting
Not Applicable
Post-COVID-19-Treatment StudyU09.9Post COVID-19 condition, unspecified
DRKS00033476Johannes Gutenberg-Universität Mainz, Abteilung für Klinische Psychologie, Psychotherapie und Experimentelle Psychotherapie zusammen mit der Hochschulambulanz für Forschung und Lehre der Poliklinischen Institutsambulanz für Psychotherapie54
Active, not recruiting
Not Applicable
Acupuncture treatment of people with residual symptoms of COVID-19 infectioSequelae of other specified infectious and parasitic diseasesB34.2
RBR-29bt5qtHospital do Servidor Público Municipal
Terminated
Phase 3
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)COVID-19
NCT04348656Hamilton Health Sciences Corporation940
Active, not recruiting
Phase 1
Treatments of COVID-19 in primary care in the NetherlandsPatients with symptomatic COVID-19 in the community and in primary care, who are at higher risk of a complicated illness course.MedDRA version: 23.0Level: PTClassification code: 10084268Term: COVID-19 Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]
CTIS2022-501559-99-00Maastricht University682